Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The transcript discusses various products and pipeline. We need to look for any statement about deals, orders, contracts, projects, customers, sites, or programs getting individually larger over time. Scanning the transcript: There is discussion about EYLEA, Dupixent, Libtayo, aflibercept 8 mg, oncology pipeline, etc. Management talks about growth, market share, approvals, but I don't see any explicit statement about the size of individual deals or contracts escalating. They mention "expanding into new indications" and "additional launches" but that's about more indications, not larger unit size per engagement. They talk about "steady growth" and "market share gains" but not about the average size of orders or contracts increasing. There is mention of "aflibercept 8 milligrams" as a potential new standard of care, but that's about a product with longer dosing intervals, not about deal size. They talk about "confirmatory Phase 3 studies" and "regulatory submissions" but not about larger contracts. No mention of customers starting at higher levels, or follow-on commitments at multiples, or initial commitments as full deployments. The transcript is mostly about clinical progress, commercial performance, and financial guidance. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.